Galectin Therapeutics Inc (GALT) Q4 2025 Earnings Call Transcript

Why It Matters

The extended cash runway and regulatory alignment de‑risk Altimmune’s path to market, positioning PEMB as a potential differentiated therapy in the rapidly expanding NASH market.

Key Takeaways

• Phase III NASH trial to enroll ~1,800 patients worldwide
• Cash runway extended to 2028 after $340M pro forma cash
• PEMB received FDA Breakthrough Therapy designation for NASH
• Phase II data showed 7.5% weight loss and fibrosis improvement
• Physician surveys predict high adoption, >70% likely to prescribe

Pulse Analysis

Altimmune’s latest earnings call underscores a pivotal moment for the company as it transitions from Phase II success to a global Phase III program. By securing $340 million in cash, the firm not only safeguards its operational runway through 2028 but also signals confidence to investors and partners. This financial cushion enables the ambitious enrollment of roughly 1,800 patients across North America, Europe, and Asia, a scale that rivals the largest NASH trials to date and positions PEMB for accelerated approval pathways if primary endpoints are met.

The clinical data driving this momentum are compelling. In the Phase II MATCH study, the 1.8 mg dose of PEMB delivered statistically significant reductions in ELF scores, liver stiffness, ALT, and cT1, alongside a sustained 7.5% weight loss without plateauing. Equally important, the safety profile remained favorable, with minimal gastrointestinal events and low discontinuation rates, addressing a key adherence barrier that has hampered many injectable NASH candidates. The addition of a 2.4 mg arm in Phase III aims to explore further efficacy gains, particularly in weight reduction and fibrosis reversal, while the simple one‑ or two‑step titration could become a market differentiator.

Beyond the data, market dynamics amplify PEMB’s potential impact. Physician surveys reveal that more than 70% of hepatologists are likely to prescribe the therapy, reflecting strong demand for a treatment that combines metabolic benefits with liver‑specific efficacy. With FDA Breakthrough Therapy designation already secured, Altimmune is well‑positioned to navigate regulatory scrutiny and accelerate time‑to‑market. If the Phase III outcomes align with Phase II trends, PEMB could capture a sizable share of the projected $30 billion NASH therapeutic market, offering investors a high‑growth opportunity anchored in robust clinical and commercial fundamentals.